La UB, CSIC and UAB are licensed a patent the company Janus Developments for the treatment of inflammatory diseases.
patented research results may be useful in the medium term in the treatment of various inflammatory diseases.
Barcelona, January 2013.- after a long history of collaboration between three research groups of the UB, CSIC and UAB in interference (siRNA) nucleic acids research, found the solution in inhibiting, among others, genes involved in inflammatory diseases, such as e.g. those related to the action of the Factor of Tumor Necrosis (TNF-alpha). As result of this project in 2010 applied for a patent that has been recently licensed the company Janus Developments SL
the results obtained so far do foresee that, in the long term, these products could be useful in the treatment of diseases such as Crohn’s disease, Ulcerative Colitis, asthma, psoriasis and even some types of oncological diseases inflammatory. Since in these diseases, the TNF-alpha promotes disease state, it is clear that regulation of this factor could allow a considerable improvement in patients when it can finally be applied after clinical development.
Patented search results have been obtained from the joint research of the research groups at different universities and centers. By the CSIC has participated the Group’s chemistry of nucleic acids, led by Dr. Ramon Eritja, of the Institute of chemistry advanced (IQAC), by the UB, has participated the metabolic regulation in inflammation and Diabetes group, led by Dr. José Carlos Perales, and UAB participated research group in inflammation and tolerance, led by Dr. Ester Fernández.
Janus Developments SL, company which aims to bring basic industry research so that inventions could actually reach end-users, has licensed this patent in order to continue maturing the development of this potential therapy to begin pre-clinical studies. In the future, is expected to incorporate other partners to the project to be able to finance their full clinical development.
The FBG as a Centre for the transfer of knowledge, technology and innovation of the UB has led the negotiations of the research group of the UB with the Janus Developments company.
